AstraZeneca is a global, innovation-driven biopharmaceutical company operating in more than 100 countries with a primary focus on the discovery, development and commercialization of prescription medicines.
On October 20, 2015 AstraZeneca opened its new factory in the industrial park “Vorsino” (Kaluga region, Russia). The total investments exceeded USD 224 mln. As the preparations of the official opening ceremony were organized, Business Sweden's role was to invite high-profile visitors from the Swedish and Russian political spheres. Eventually, the event gathered over 150 participants. Among the high level guests were the State Secretary Agneta Karlsson, First Deputy Minister of Healthcare of Russia Igor Kagramanyan, Deputy Minister of Industry and Trade of Russia Sergey Tsyb and CEO of AstraZeneca Pascal Soriot.
Another point of collaboration between Business Sweden and AstraZeneca was the roundtable discussion on investment policy, which also took place on October 20, 2015 and gathered managers from some of the largest Swedish companies investing in Russia, including IKEA, Volvo Trucks and CE, Sandvik, Alfa Laval, Atlas Copco and SKF. High-level officials representing the legislative and executive bodies, including Vice-minister level, attended the meeting. The discussion was fruitful and contributed to new insights on how to improve business conditions in Russia.
“It’s always a challenge to arrange meetings at the highest decision-making level, especially when it comes to Russian officials. The key to our successful result is our vast network of contacts both in business community and public sector, including authorities on federal and regional levels”, - says Andreas Giallourakis, Trade Commissioner to Russia at Business Sweden office in Moscow.
“We are proud to have such a reliable and competent partner as Business Sweden. Foreign investors in Russia face similar challenges in doing business, often regardless of the industry they work for. It’s great to have a common business platform that creates opportunities for the discussion of the business prospects both internally and with external experts, including the representatives of the government authorities”, - says Irina Ivanishcheva, Corporate Affairs and Legal Director, AstraZeneca Russia & Eurasia.